Molecular marker for the diagnosis of fibroadenoma
Posted in the Breast Cancer Forum
#1 Sep 25, 2012
US patent issued on Sept. 11, 2012 Described the use of constitutively active mutants of the prolactin receptor (PRLR) for the diagnosis or prognosis of patients with fibroadenoma, multiple fibroadenomas and hypermastia. In mutants, the Ile residue at position 76 or at position 146 of the mature form of PRLR has been substituted by another amino acid residue. Molecular analysis of these receptor mutants can be used for evaluating the risk of fibroadenoma evolving to multiple fibroadenomas.
Source: http://www.sciclips.com/sciclips/biomarker-ne... [Patent%20News]
Add your comments below
|Breast cancer patients could be spared chemothe...||Sat||Stephany McDowell||1|
|Side Affects AFTER CHEMO (Nov '06)||Aug 4||PFfff||292|
|Why Suzanne Somers loves bioidentical hormones (Jun '09)||Jul '16||Chaimpie||93|
|I'm scared I might have male breast cancer =(!(... (Oct '06)||Jul '16||Zaid||883|
|Study tests new breast cancer drug in African A...||Jul '16||Oh No You Di-nt||1|
|PLEASE HELP. possible cancer?||Jul '16||PFfff||2|
|Billy Joel to join Cuomo on NY breast cancer mo...||Jun '16||Shevon Drake||1|
Find what you want!
Search Breast Cancer Forum Now
Copyright © 2016 Topix LLC